Northwire Canada EditionSaturday, July 18, 2026
Sign inSubscribe
Northwire
⌕
AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0% AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0%

Healthcare

Page 120
  1. Oct 14, 2025 · 20:37 · MBIO

    Mindbio preparing for phase 3 clinical trials

    Mindbio preparing for phase 3 clinical trials

    01
  2. Oct 14, 2025 · 20:07 · BIOV

    None

    Biovaxys licensee SpayVac talks research results

    02
  3. Oct 14, 2025 · 20:00 · ONCO

    Onco-Innovations Announces Private Placement

    Onco-Innovations Announces Private Placement

    03
  4. Oct 14, 2025 · 19:24 · CPH

    Cipher Pharmaceuticals receives arbitration award

    Cipher Pharmaceuticals receives arbitration award

    04
  5. Oct 14, 2025 · 16:30 · VPT

    Ventripoint Announces Closing of Second and Final Tranche of Non-Brokered Convertible Debenture Units Private Placement

    Ventripoint Announces Closing of Second and Final Tranche of Non-Brokered Convertible Debenture Units Private Placement

    05
  6. Oct 14, 2025 · 11:22 · SHRX

    Sharp Therapeutics Arranges Non-Brokered Private Placement

    Sharp Therapeutics Arranges Non-Brokered Private Placement

    06
  7. Oct 14, 2025 · 08:10 · MBIO

    None

    MindBio Prepares for Phase 3 Clinical Trials

    07
  8. Oct 14, 2025 · 08:00 · BIOV

    BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission Process

    BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission Process

    08
  9. Oct 14, 2025 · 07:45 · CPH

    Cipher Pharmaceuticals Receives Successful Arbitration Award

    Cipher Pharmaceuticals Receives Successful Arbitration Award

    09
  10. Oct 13, 2025 · 07:30 · BCT

    None

    BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

    10
  11. Oct 10, 2025 · 17:01 · MSCL

    Satellos releases new Duchenne trial data

    Satellos releases new Duchenne trial data

    11
  12. Oct 10, 2025 · 16:01 · PREV

    PreveCeutical Announces Results from Annual General and Special Meeting and Increase to Size of Non-Brokered Private Placement

    PreveCeutical Announces Results from Annual General and Special Meeting and Increase to Size of Non-Brokered Private Placement

    12
  13. Oct 10, 2025 · 09:45 · MSCL

    Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy

    Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy

    13
  14. Oct 09, 2025 · 19:04 · HEM

    Hemostemix applies for vascular dementia study approval

    Hemostemix applies for vascular dementia study approval

    14
← Newer Older →